Contact Information
Steven T. Rosen, M.D.
  • Provost and Chief Scientific Officer
  • Director, Comprehensive Cancer Center
  • Irell & Manella Cancer Center Director's Distinguished Chair

Primary Specialties

Departments/Division/Program

Biography

Steven T. Rosen, M.D., is provost and chief scientific officer for City of Hope and a member of City of Hope’s Executive Team. He also is director of the Comprehensive Cancer Center and holds the Irell & Manella Cancer Center Director's Distinguished Chair, and he is responsible for Beckman Research Institute and the Irell & Manella Graduate School of Biological Sciences.
 
Rosen sets the scientific direction of City of Hope, shaping the research and educational vision for the biomedical research, treatment and education institution. Working closely and collaboratively with City of Hope’s scientists, clinicians and administrative leaders, he develops strategies that contribute to the organization’s mission.
 
Prior to joining City of Hope, Rosen was the Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine at Northwestern University in Chicago. He served for 24 years as director of Northwestern’s Robert H. Lurie Comprehensive Cancer Center. Under his leadership, the center received continuous National Cancer Institute (NCI) funding beginning in 1993 and built nationally recognized programs in laboratory sciences, clinical investigations, translational research and cancer prevention and control. The center attained comprehensive status in 1997.
 
Rosen has published more than 400 original reports, editorials, books and book chapters. His research has been funded by the National Cancer Institute, American Cancer Society, Leukemia & Lymphoma Society of America and Multiple Myeloma Research Foundation. He also has served as an adviser for several of these organizations and on the external advisory boards of more than a dozen NCI-designated Comprehensive Cancer Centers. He is the current editor-in-chief of the journal Cancer Treatment & Research.
 
Recognized as one of the Best Doctors in America, Rosen is a recipient of the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital and the Man of Distinction Award from the Israel Cancer Research Fund. He earned his bachelor’s degree and medical degree with distinction from Northwestern University.
 

Professional Experience

2014-present, Provost and Chief Scientific Officer, City of Hope, Duarte, CA
1989-2014, Director, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University,  Chicago, IL
1989-2014, Director of Cancer Programs Northwestern Memorial Hospital, Chicago, IL
1989-2014, Genevieve Teuton Professor of Medicine, Feinberg School of Medicine at Northwestern  University, Chicago, IL
1981-2014, Attending Physician Northwestern Memorial Hospital, Chicago, IL
1982-1986 Assistant Professor, Department of Medicine, Northwestern Univ. Medical School, Chicago, IL
1981-1987, Staff Physician, Division of Hematology/Oncology, Veterans Administration Lakeside  Medical Center, Chicago, IL
1981, Associate, Department of Medicine, Northwestern Univ. Medical School, Chicago, IL
 
 
 

Education

EDUCATION
1976, M.D., Northwestern University Medical School, Chicago, IL
1972, B.M., Honors Program, Northwestern University, Evanston, IL
 
TRAINING
1979-1981, Fellowship in Hematology/Oncology, National Cancer Institute, Bethesda, MD
1977-1979, Residency in Internal Medicine, Northwestern Memorial Hospital, Chicago, IL

Honors and Awards

HONORS
1969-1972, Honors Medical Program, Northwestern University
1976, Alpha Omega Alpha
1976, M.D. with Distinction, Northwestern University
1986, Participant, President's Cancer Panel, Chicago
1986, Member, Central Society for Clinical Research
2011, Member, NCI Fredericks Scientific Advisory Committee
2012, Chairman, Leukemia & Lymphoma Society of America Medical/Science Committee
 
AWARDS
1994, Alumni Merit Award, Northwestern University
1994, Martin Luther King Humanitarian Award, Northwestern Memorial Hospital
2011, Man of Distinction Award, Israel Cancer Research Fund

Research

Active
P30 CA060553-19 (Rosen) 08/01/93 – 07/31/18
NIH/NCI
The Robert H. Lurie Comprehensive Cancer Center
The goals of this Cancer Center Support Grant are to conduct and support cancer research and to integrate cancer-related research throughout the university; to coordinate and integrate cancer-related activities of the University including community outreach initiatives; to develop and conduct cancer education programs; to promote and participate in state-of-the-are care of cancer patients at the affiliated hospitals of the McGaw Medical Center of Northwestern University and; to develop and implement the initiatives in cancer prevention and control research.  These goals are accomplished through the activities of the 19 establish programs and 15 shared resources.
 
P30 CA060553-18S4 (Rosen) 08/01/01 – 07/31/14
NIH/NCI
CURE Program at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. 
The CURE Program enables the Cancer Center to bring 10-12 high school and undergraduate students who are highly interested in the sciences to conduct laboratory research in various areas of cancer during the summer months.  The faculty chosen to be preceptors are established NIH-funded investigators who belong to one of nine programs of the Lurie Cancer Center.  In addition to the laboratory investigations, the students meet weekly for a seminar series where faculty are invited to lecture on various aspects of cancer research and career guidance.  Twenty-eight percent have chosen to pursue post-graduate training in medical school, graduate school or masters in public health.  Five percent have accepted jobs working in or affiliated with a laboratory. 
 
U54 CA151880-04 (Mirkin/Rosen) 09/21/10 - 07/31/15
NIH/NCI
Nanomaterials for Cancer Diagnostics and Therapeutics
The Northwestern University Center for Cancer Nanotechnology Excellence (NU-CCNE) will draw upon NU’s outstanding research strengths in the areas of cancer research, nanoscience, bioimaging and nano-tool development. The long-term objective of the NU-CCNE is to design and test nanomaterials and nanodevices for application in the clinic, ultimately facilitating the translation of novel and innovative nanoscale technologies that significantly improve cancer prevention, detection, diagnosis, and treatment.
 
T32 CA079447-15 (Rosen) 01/13/99 - 07/31/15
NIH/NCI
Clinical Oncology Research Training Program
The goal of this project is to provide funding for medical hematology/oncology fellows to carry out laboratory cancer research.
 
U01 CA116875-05 (Rosen) 09/16/05 – 08/30/13 (NCE)
NIH/NCI
Chicago Cancer Navigation Project
The purpose of this project is to develop a navigation intervention for lower socioeconomic status persons in Chicago with a positive screening test for cancer of the prostate, colorectum, breast or cervix.  The patient navigator program will interface with individuals who, although poor, have guaranteed financial access to follow-up care.
 
01-2011-030 (Rosen) 10/01/11 – 09/30/12
01-2012-026b (Rosen) 10/01/12 – 09/30/13
Avon Products Foundation
Avon Center of Excellence
The goals of the Avon Foundation projects are:  (1) Characterizing and defining the molecular mechanisms of breast cancer growth, survival, and metastasis; (2) Developing model systems to evaluate new agents or approaches for the treatment and prevention of breast cancer; and (3) Initiating clinical studies in breast cancer that will define molecular markers for the treatment or prevention of breast cancer.
 

Publications

1. Moalli PA, Pillay S, Krett N, Rosen ST.  Alternately Spliced Glucocorticoid Receptor Messenger RNAs in Glucocorticoid-resistant Human Multiple Myeloma Cells.  Cancer Research.  1993 53:3877-3879.
PMID:8358712

2. Gandhi V, Ayres M, Halgren RG, Krett NL, Newman R, Rosen ST.  8-Chloro-cAMP and 8-Chloro-adenosine Act by the Same Mechanism in Multiple Myeloma Cells.  Cancer Research 2001 61:5474-5479. PMID:11454694

3. Krett NL, Davies KM, Ayers M, Ma C, Nabhan C, Gandhi V, Rosen ST.  8-Amino-Adenosine is a potential therapeutic agent for multiple myeloma. Molecular Cancer Therapeutics 2004 3:1411-1420. PMID:15542780

4. Nabhan C, Patton D, Gordon L, Riley MB, Kuzel TM, Tallman M, Rosen ST. A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL). Leukemia and Lymphoma 2004 45:2269-2273. PMID:15512816

5. Ghias K, Ma C, Gandhi V, Krett N, Rosen ST. 8-Amino-Adenosine induces loss of phosphorylation of p38 MAPK, ERK1/2, and Akt Kinase: Role in induction of apoptosis in multiple myeloma. Molecular Cancer Therapeutics 2005 4:569-577. PMID:15827330

6. Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett N, Rosen ST. Enzastaurin (LY317615), a protein kinase C beta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Molecular Cancer Therapeutics  2006 5:1783-1789. PMID:16891464

7. Sánchez-Vega B, Krett N, Rosen ST, Gandhi V. Glucocorticoid Receptor Transcriptional Isoforms and Resistance in Multiple Myeloma Cells. Molecular Cancer Therapeutics 2006 5:3062-3070. PMID:17172408

8. Chen Y, Peterson LC, Dittmann D, Evens A, Rosen ST, Khoong A, Shankey TV, Forman M, Gupta R,  Goolsby C. Comparative Analysis of Flow Cytometric Techniques in Assessment of ZAP-70 Expression in Relation to IgVH Mutational Status in Chronic Lymphocytic Leukemia (CLL). Am J Clin Pathol. 2007 Feb;127(2):182-91 PMID:17210531

9. Grugan KD, Ma C, Singhal S, Krett NL, Rosen ST. Dual Regulation of Glucocorticoid-Induced Leucine Zipper (GILZ) by the Glucocorticoid Receptor and the PI3-kinase/AKT Pathways in Multiple Myeloma. J Steroid Biochem &  Molecular Biol. 2008 110:244-254. PMID:18499442

10. Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL, Rosen ST. Targeting Glucose Consumption and Autophagy in Myeloma with the Novel Nucleoside Analogue 8-Amino-Adenosine. J. Biol. Chem. 2009 284(39):26816-30.   PMC2785370

11. Dennison J, Shanmugam M, Krett N, Medeiros J, Neelapu S, Rosen ST, Gandi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood. 2010 Dec 16;116(25):5622-30. Epub 2010 Sep 15..  PMC3031409

12. Tessel MA, Benham AL, Krett NL, Rosen ST, Gunaratne PH.  Role for microRNAs in  regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer. 2011 Jun;2(3):182-9. . PMID:21761344

13. Rovedo MA, Krett NL, Rosen ST.  Inhibition of glycogen synthase kinase-3 increases cytotoxicity of enzastaurin.  Journal of Investigative Dermatology 2011, Jul:131(7): 1442-1449.  PMC3116015.

14. McBrayer SK, Yarrington M, Qian J, Feng G, Shanmugam M, Gandhi V, Krett NL, Rosen ST.  Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.  PLoS One. 2012;7(7):e41455. Epub 2012 Jul 27.  PMC3407247

15. Cheng JC, McBrayer SK, Rosen ST, Shanmugam M. Expression and Phosphorylation of the AS160_v2 Splice Variant supports GLUT4 Activation and the Warburg Effect in Multiple Myeloma. Cancer & Metabolism 2013 , 1:14 (29 May 2013

Location

City of Hope - Main campus
1500 E. Duarte Rd.
Duarte, CA 91010

Media Expertise

  • Hematologic malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma